

# Gail V Matthews

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2897186/publications.pdf>

Version: 2024-02-01

158  
papers

6,809  
citations

66315

42  
h-index

74108

75  
g-index

165  
all docs

165  
docs citations

165  
times ranked

6922  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009–2019. <i>Clinical Infectious Diseases</i> , 2022, 74, 1804-1811.	2.9	11
2	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. <i>Clinical Infectious Diseases</i> , 2022, 75, 3-10.	2.9	4
3	High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH Study. <i>Hepatology Communications</i> , 2022, 6, 496-512.	2.0	10
4	Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 210-216.	7.0	486
5	Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 271-279.	1.0	3
6	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The STOP-C Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1809-1819.	2.9	11
7	Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH cohort. <i>Journal of Viral Hepatitis</i> , 2022, 29, 661-676.	1.0	7
8	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. <i>Nature Microbiology</i> , 2022, 7, 896-908.	5.9	32
9	Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. <i>Lancet HIV</i> , 2022, 9, e414-e427.	2.1	23
10	Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infection. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100093.	0.4	3
11	Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e2164-e2172.	2.9	30
12	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1392-1400.	2.9	26
13	Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 39-56.	3.7	68
14	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. <i>Journal of Hepatology</i> , 2021, 74, 293-302.	1.8	27
15	Concomitant Marked Decline in Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Respiratory Viruses Among Symptomatic Patients Following Public Health Interventions in Australia: Data from St Vincent's Hospital and Associated Screening Clinics, Sydney, NSW. <i>Clinical Infectious Diseases</i> , 2021, 72, e649-e651.	2.9	39
16	Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection. <i>Medical Journal of Australia</i> , 2021, 214, 279-280.	0.8	41
17	Characteristics Associated with Monitoring and Treatment of Chronic Hepatitis B in a Large Cohort of Australian Adults. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	0
18	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2037-2044.	2.9	9

#	ARTICLE	IF	CITATIONS
19	Elimination of hepatitis C among HIV-positive population in Asia: old and new challenges. <i>Future Virology</i> , 2021, 16, 407-417.	0.9	0
20	SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. <i>PLoS Medicine</i> , 2021, 18, e1003656.	3.9	109
21	Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 12, 100193.	1.3	29
22	Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. <i>International Journal of Drug Policy</i> , 2021, 96, 103422.	1.6	15
23	Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. <i>Medical Journal of Australia</i> , 2021, 215, 332-333.	0.8	8
24	One-third of people who inject drugs are at risk of incomplete treatment for <i>Staphylococcus aureus</i> bacteraemia: a retrospective medical record review. <i>International Journal of Infectious Diseases</i> , 2021, 112, 63-65.	1.5	1
25	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , 2021, 75, 829-839.	1.8	27
26	Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virus-positive Gay and Bisexual Men?. <i>Clinical Infectious Diseases</i> , 2020, 70, 106-113.	2.9	11
27	Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1502-1510.	2.9	46
28	Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. <i>Hepatology</i> , 2020, 72, 7-18.	3.6	24
29	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2369-2376.	2.9	19
30	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. <i>Clinical Infectious Diseases</i> , 2020, 71, e115-e124.	2.9	53
31	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	1.8	30
32	Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1028-1029.	3.7	1
33	Modeling based response guided therapy in subjects with recent hepatitis C infection. <i>Antiviral Research</i> , 2020, 180, 104862.	1.9	6
34	The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 646.	0.7	11
35	Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. <i>Aids</i> , 2020, 34, 1347-1358.	1.0	12
36	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 840-851.	0.4	36

#	ARTICLE	IF	CITATIONS
37	Novel Hepatitis C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. <i>Journal of Infectious Diseases</i> , 2020, 222, S758-S772.	1.9	15
38	Universal screening for hepatitis C virus infection should be linked to universal treatment access. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 321-322.	8.2	2
39	Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England. <i>Journal of Viral Hepatitis</i> , 2020, 27, 721-730.	1.0	16
40	Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand. <i>Liver International</i> , 2020, 40, 2104-2109.	1.9	10
41	Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO): An open-label, single-arm, phase 4, multicentre trial. <i>Health Science Reports</i> , 2020, 3, e151.	0.6	4
42	Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. <i>Sexual Health</i> , 2020, 17, 223.	0.4	8
43	Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection—Lessons for Functional HBV Cure?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 527-533.	0.9	20
44	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , 2019, 70, e110.	1.8	2
45	Cure and Control: What Will It Take to Eliminate HCV?. <i>Topics in Medicinal Chemistry</i> , 2019, , 447-490.	0.4	2
46	THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. <i>Journal of Hepatology</i> , 2019, 70, e231.	1.8	4
47	A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. <i>Journal of the International AIDS Society</i> , 2019, 22, e25222.	1.2	6
48	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	3.7	342
49	Management of acute HCV in the era of direct-acting antivirals: implications for elimination. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 256-257.	3.7	5
50	Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 31-37.	1.3	29
51	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. <i>Infection, Genetics and Evolution</i> , 2019, 69, 76-84.	1.0	6
52	Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. <i>Hepatology</i> , 2019, 69, 1135-1150.	3.6	15
53	Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. <i>Journal of the International AIDS Society</i> , 2018, 21, e25051.	1.2	40
54	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 153-161.	3.7	231

#	ARTICLE	IF	CITATIONS
55	Looking at the positives: proactive management of STIs in people with HIV. <i>AIDS Research and Therapy</i> , 2018, 15, 28.	0.7	7
56	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	1.6	58
57	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	1.6	22
58	Management of acute HCV infection in the era of direct-acting antiviral therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 412-424.	8.2	62
59	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 371-393.	1.9	27
60	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017, 11, 188-198.	1.9	2
61	Direct-acting antivirals for acute HCV: how short can we go?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 316-318.	3.7	2
62	HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. <i>Current HIV/AIDS Reports</i> , 2017, 14, 110-121.	1.1	46
63	Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database. <i>Sexual Health</i> , 2017, 14, 345.	0.4	5
64	Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review. <i>Sexual Health</i> , 2017, 14, 28.	0.4	60
65	A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. <i>Journal of Viral Hepatitis</i> , 2017, 24, 404-411.	1.0	23
66	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). <i>Hepatology Communications</i> , 2017, 1, 736-747.	2.0	8
67	Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data. <i>BMC Infectious Diseases</i> , 2017, 17, 740.	1.3	5
68	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , 2017, 1, 379-390.	2.0	26
69	The Impact of Ribavirin Plasma Concentration on the Efficacy of the Interferon-Sparing Regimen, Sofosbuvir and Ribavirin. <i>Antiviral Therapy</i> , 2016, 21, 127-132.	0.6	3
70	Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. <i>Aids</i> , 2016, 30, 1597-1606.	1.0	15
71	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. <i>Liver International</i> , 2016, 36, 1774-1782.	1.9	8
72	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 465-465.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 317-327.	3.7	80
74	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). <i>Journal of Hepatology</i> , 2016, 65, 1086-1093.	1.8	36
75	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE II study. <i>Hepatology</i> , 2016, 64, 1911-1921.	3.6	50
76	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 425-434.	0.6	6
77	Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw035.	0.4	19
78	Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 739-747.	1.9	10
79	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. <i>Virology Journal</i> , 2016, 13, 32.	1.4	10
80	Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw105.	0.4	16
81	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2016, 16, 241.	1.3	5
82	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2016, 37, 252-258.	1.0	13
83	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. <i>PLoS ONE</i> , 2016, 11, e0150655.	1.1	15
84	Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men. <i>PLoS ONE</i> , 2016, 11, e0162002.	1.1	8
85	Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C. <i>Antiviral Therapy</i> , 2015, 20, 199-208.	0.6	21
86	Reply. <i>Hepatology</i> , 2015, 61, 409-409.	3.6	0
87	Enhancing the detection and management of acute hepatitis C virus infection. <i>International Journal of Drug Policy</i> , 2015, 26, 899-910.	1.6	16
88	Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. <i>Lancet HIV</i> , 2015, 2, e319-e327.	2.1	285
89	Interferon $\lambda$ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 583-589.	1.2	3
90	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. <i>International Journal of Drug Policy</i> , 2015, 26, 976-983.	1.6	44

#	ARTICLE	IF	CITATIONS
91	A Comparison of Seminal Hepatitis C Virus (HCV) RNA Levels During Recent and Chronic HCV Infection in HIV-Infected and HIV-Uninfected Individuals. <i>Journal of Infectious Diseases</i> , 2015, 211, 736-743.	1.9	30
92	The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0131437.	1.1	48
93	Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 947-954.	0.3	6
94	Decline in Serum 25 Hydroxyvitamin D Levels in HIV/Hbv-Coinfected Patients after Long-Term Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2014, 19, 41-49.	0.6	6
95	Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial. <i>PLoS ONE</i> , 2014, 9, e99530.	1.1	5
96	Lipopolysaccharide, Immune Activation, and Liver Abnormalities in HIV/Hepatitis B Virus (HBV) Coinfected Individuals Receiving HBV-Active Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 210, 745-751.	1.9	29
97	Dynamics of HCV RNA levels during acute hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2014, 86, 1722-1729.	2.5	26
98	<i>ITPA</i> genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. <i>Hepatology</i> , 2014, 59, 2152-2160.	3.6	25
99	Advanced liver fibrosis by transient elastography, <i>F</i> ibrosis 4, and alanine aminotransferase/platelet ratio index among <i>A</i> sian hepatitis <i>C</i> with and without human immunodeficiency virus infection: Role of vitamin <i>D</i> levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1706-1714.	1.4	34
100	CXCL-10, IL-12 and IL-21 are not immunological predictors of HBeAg seroconversion in HIV-1/HBV coinfection following HBV-active antiretroviral therapy (ART). <i>Antiviral Therapy</i> , 2014, 19, 429-433.	0.6	4
101	Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral-Based Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, S118-S124.	2.9	43
102	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. <i>Hepatology</i> , 2013, 57, 2124-2134.	3.6	61
103	Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2013, 56, e87-e94.	2.9	69
104	Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements. <i>Clinical Infectious Diseases</i> , 2013, 57, 1014-1020.	2.9	97
105	Sexually transmitted hepatitis C infection. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 66-72.	1.3	100
106	Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men. <i>Sexual Health</i> , 2013, 10, 9.	0.4	19
107	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. <i>PLoS ONE</i> , 2013, 8, e80003.	1.1	9
108	Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals. <i>PLoS ONE</i> , 2013, 8, e61297.	1.1	41

#	ARTICLE	IF	CITATIONS
109	Impaired Hepatitis C Virus (HCV) Specific Interferon- $\beta$ Responses in Individuals With HIV Who Acquire HCV Infection: Correlation With CD4+ T-Cell Counts. <i>Journal of Infectious Diseases</i> , 2012, 206, 1568-1576.	1.9	21
110	Virological responses during treatment for recent hepatitis C virus. <i>Aids</i> , 2012, 26, 1653-1661.	1.0	27
111	In vitro replication phenotype of a novel ( $\sim$ 1G) hepatitis B virus variant associated with HIV co-infection. <i>Journal of Medical Virology</i> , 2012, 84, 1166-1176.	2.5	10
112	Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. <i>Hepatology</i> , 2012, 55, 1058-1069.	3.6	82
113	Effect of pegylated interferon- $\alpha$ treatment on mental health during recent hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 957-965.	1.4	38
114	Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfecting subjects initiating HBV-active antiretroviral therapy in Thailand. <i>AIDS Research and Therapy</i> , 2012, 9, 6.	0.7	24
115	Treatment of acute HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 265-274.	8.2	53
116	Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. <i>Genome Medicine</i> , 2011, 3, 57.	3.6	62
117	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. <i>Journal of Hepatology</i> , 2011, 55, 76-85.	1.8	53
118	Future of hepatitis C therapy. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 508-513.	1.5	28
119	HIV and hepatitis C coinfection. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 449-450.	1.5	6
120	Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. <i>Aids</i> , 2011, 25, 197-205.	1.0	44
121	Participants' perspectives of high resolution anoscopy. <i>Sexual Health</i> , 2011, 8, 255.	0.4	7
122	Participants' perspectives of self-collected anal cytological swabs. <i>Sexual Health</i> , 2011, 8, 257.	0.4	9
123	Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?. <i>Hepatology</i> , 2011, 53, 1055-1056.	3.6	4
124	Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. <i>Aids</i> , 2011, 25, 1727-1735.	1.0	44
125	IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. <i>PLoS Medicine</i> , 2011, 8, e1001092.	3.9	107
126	Factors Associated with Elevated ALT in an International HIV/HBV Co-Infected Cohort on Long-Term HAART. <i>PLoS ONE</i> , 2011, 6, e26482.	1.1	10



#	ARTICLE	IF	CITATIONS
127	Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. <i>Aids</i> , 2010, 24, 1799-1812.	1.0	217
128	Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naïve HIV-1/2/3 HBV coinfection in Thailand. <i>Antiviral Therapy</i> , 2010, 15, 917-922.	0.6	29
129	HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. <i>Virology</i> , 2010, 405, 539-547.	1.1	28
130	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 1216-1224.	3.6	156
131	No Increase in Hepatitis B Virus (HBV)-Specific CD8 <sup>+</sup> T Cells in Patients with HIV-1-HBV Coinfections following HBV-Active Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2010, 84, 2657-2665.	1.5	18
132	Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. <i>Sexually Transmitted Infections</i> , 2010, 86, 25-28.	0.8	84
133	Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 123-135.e2.	0.6	157
134	Tenofovir. , 2010, , 2613-2626.		1
135	Reply to Vogel et al.. <i>Clinical Infectious Diseases</i> , 2009, 49, 319-320.	2.9	0
136	Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection. <i>Journal of Virology</i> , 2009, 83, 7649-7658.	1.5	35
137	Immunopathogenesis of Hepatic Flare in HIV/Hepatitis B Virus (HBV)-Coinfected Individuals after the Initiation of HBV-Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2009, 199, 974-981.	1.9	83
138	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfecting individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. <i>Hepatology</i> , 2009, 49, 1113-1121.	3.6	22
139	Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men. <i>Gastroenterology</i> , 2009, 136, 1609-1617.	0.6	285
140	Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfecting individuals. <i>Aids</i> , 2009, 23, 1707-1715.	1.0	50
141	Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. <i>Hepatology</i> , 2008, 48, 741-749.	3.6	24
142	A randomized trial of combination hepatitis B therapy in HIV/HBV coinfecting antiretroviral naïve individuals in Thailand. <i>Hepatology</i> , 2008, 48, 1062-1069.	3.6	121
143	HIV and hepatitis C coinfection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1000-1008.	1.4	56
144	The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure. <i>Journal of Hepatology</i> , 2008, 49, 305-307.	1.8	6

#	ARTICLE	IF	CITATIONS
145	Invasive Amebiasis in Men Who Have Sex with Men, Australia. <i>Emerging Infectious Diseases</i> , 2008, 14, 1141-1143.	2.0	54
146	Hepatitis virus immune restoration disease of the liver. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 446-452.	1.5	16
147	The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. <i>Aids</i> , 2008, 22, 947-955.	1.0	42
148	Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. <i>Aids</i> , 2007, 21, 1701-1710.	1.0	36
149	Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al.. <i>Aids</i> , 2007, 21, 2112-2113.	1.0	62
150	Response to Schmutz et al., "Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection". <i>Aids</i> , 2007, 21, 777-778.	1.0	6
151	The management of HIV and hepatitis B coinfection. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 16-21.	1.3	15
152	Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. <i>Antiviral Therapy</i> , 2007, 12, 119-22.	0.6	23
153	Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. <i>Aids</i> , 2006, 20, 863-870.	1.0	159
154	Treatment for Hepatitis C Virus Infection among Current Injection Drug Users in Australia. <i>Clinical Infectious Diseases</i> , 2005, 40, S325-S329.	2.9	55
155	Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. <i>Aids</i> , 2002, 16, 75-83.	1.0	268
156	Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. <i>Aids</i> , 2002, 16, 53-61.	1.0	93
157	Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. <i>Blood</i> , 2000, 96, 2730-2734.	0.6	183
158	Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0